EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Favorable Anti-inflammatory and Anti-fibrotic Activity In Vitro

被引：0
|
作者：
Li, Yang [1 ]
Chau, Mary D. [1 ]
Wang, Guoqiang [1 ]
Or, Yat Sun [1 ]
Jiang, Lijuan [1 ]
机构：
[1] Enanta Pharmaceut Inc, Watertown, MA USA
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1596
引用
收藏
页码：791A / 791A
页数：1
相关论文
共 50 条
  • [41] Total Synthesis and Pharmacological Characterization of Solomonsterol A, a Potent Marine Pregnane-X-Receptor Agonist Endowed with Anti-Inflammatory Activity
    Sepe, Valentina
    Ummarino, Raffaella
    D'Auria, Maria Valeria
    Mencarelli, Andrea
    D'Amore, Claudio
    Renga, Barbara
    Zampella, Angela
    Fiorucci, Stefano
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (13) : 4590 - 4599
  • [42] β-Amyrin, a pentacyclic triterpene, exhibits anti-fibrotic, anti-inflammatory, and anti-apoptotic effects on dimethyl nitrosamine-induced hepatic fibrosis in male rats
    Thirupathi, A.
    Silveira, P. C.
    Nesi, R. T.
    Pinho, R. A.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2017, 36 (02) : 113 - 122
  • [43] EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis
    Jiang, L. -J.
    Chau, M.
    Li, Y.
    Briand, F.
    Sulpice, T.
    Or, Y. S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S434 - S434
  • [44] IWP-121: a novel sGC stimulator that reduces blood pressure and exhibits anti-fibrotic and anti-inflammatory activities in the Dahl Salt-Sensitive rat model
    Courtney Shea
    Sheila Ranganath
    Guang Liu
    Derek Wachtel
    Peter Germano
    Jenny Tobin
    Ping Zhang
    Samuel Rivers
    G-Yoon Jamie Im
    James Sheppeck
    Jaime Masferrer
    BMC Pharmacology and Toxicology, 16 (Suppl 1)
  • [45] Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NFκB inhibition
    Rosette, Caridad
    Agan, Frances J.
    Rosette, Niccolette
    Moro, Luigi
    Mazzetti, Alessandro
    Hassan, Cesare
    Gerloni, Mara
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (03) : 172 - 180
  • [46] EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects
    Ahmad, Alaa
    Marotta, Christine
    Luo, Ed
    Oosterhaven, Jart
    van Marle, Sjoerd
    Adda, Nathalie
    JOURNAL OF HEPATOLOGY, 2022, 77 : S716 - S717
  • [47] EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis
    Sojoodi, Mozhdeh
    Wang, Yongtao
    Erstad, Derek J.
    Caravan, Peter
    Lanuti, Michael
    Qadan, Motaz
    Fuchs, Bryan C.
    Hoang, Khanh
    Or, Yat Sun
    Jiang, Lijuan
    Tanabe, Kenneth K.
    JOURNAL OF HEPATOLOGY, 2020, 73 : S453 - S453
  • [48] NO-steroids:: Potent anti-inflammatory drugs with bronchodilating activity in vitro
    Tallet, D
    Del Soldato, P
    Oudart, N
    Burgaud, JL
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (01) : 125 - 130
  • [49] A HIGHLY SELECTIVE AND POTENT FARNESOID X RECEPTOR (FXR) AGONIST EDP-305 REDUCES LIVER STEATOSIS, BALLOONING, AND NON-ALCOHOLIC FATTY LIVER DISEASE ACTIVITY (NAS) IN TWO MURINE MODELS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    Jiang, Li-Juan
    Chau, Mary
    Li, Yang
    Or, Yat Sun
    GASTROENTEROLOGY, 2018, 154 (06) : S1159 - S1159
  • [50] Anti-inflammatory and anti-fibrotic effects of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis
    Fraser, David A.
    Nohr-Meldgaard, Jacob
    Skjaeret, Tore
    Veidal, Sanne
    Feigh, Michael
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2021, 75 : S622 - S623
12345